OncoAlert OncoAlert

✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on @NEJM 
https://www.nejm.org/doi/full/10.1056/NEJMoa2312695#ap0



✅Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial 
https://www.annalsofoncology.org/article/S0923-7534(24)00105-4/fulltext



✅Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00185-X



✅Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab
https://www.jtocrr.org/article/S2666-3643(24)00045-6/fulltext



✅The Lancet Breast Cancer Commission
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00747-5/fulltext



✅Top advances of the year: Uterine cancer
https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35321

The  @OncoAlert RoundUp is Out
Covering April 5th-12th, 2024

REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration

Discussing:
 
@US_FDA
  approval trastuzumab dx
Durvalumab in Small Cell #LungCancer
ALINA  #NSCLC out on 
@NEJM
 
CD70 CART in #KidneyCancer
Adagrasib Cetux in #colorectalcancer 
and more

The Top News, publications and trials in Oncology for the week of March 28- April 4, 2024

SENOMAC out in NEJM on Breast Cancer
ACS & IARC 2022 Cancer Statistics
and more

JAVELIN Renal 101 Out on Cancer Discovery
FASTRACK II Out on Lancet Oncology
ONE SHOT (in Prostate cancer) Out on the Green Journal

Contact 02
Embark/
GETUG 18
FORMULA 509
BRCA Away